3Q Nowcasting for China, India, Indonesia, and Singapore


Our real GDP Nowcast model suggests growth markers are slowing in 3Q of this year, with pandemic management the key for further upside.
Taimur Baig, Daisy Sharma08 Jul 2021
  • China is on course to register 7.6% growth during the July-September quarter
  • Our Nowcast for India sees growth of 6.8% in 3Q, some of it helped a favourable base effect
  • Favourable base effects will allow Indonesia to register 4.7% growth in 3Q, still well below trend
  • On Singapore, our Nowcast model is tracking 5.8% growth in 3Q
Photo credit: Unsplash laurel-and-michael-evans


China

After mounting a spectacular recovery after one quarter of contraction last year, China has gone from strength to strength, making up for lost output. But has growth peaked already, with the remainder of the year likely to be characterised by policy-induced slowdown? Our Nowcast model appears to think so, with 3Q GDP growth estimated to ease to 7.6%, still somewhat helped by a favourable base effect. For the year as a whole, China remains on track to grow by around 10%, although we see tell-tale signs that the 2H21 growth will be lower than 1H21, not just on a year-on-year basis, but also sequentially.

The authorities have taken note of the strong momentum in the property markets, responding with some tightening measures. They have also removed some degree of implicit support from government-adjacent companies’ bonds, creating a ripple in the credit market. Additionally, capital markets have felt a chill from strong regulatory moves, especially in the tech sector.

Exports have been exceptionally strong, underscoring sustained global demand for goods made in China. Meeting such strong external demand has been helpful to industrial production and profits, a trend likely to last this year. Domestic demand however is a mixed story, with retail sales beginning to slow. Buoyant domestic travel and tourism have been an offset to a near-ban on visitor arrivals.





India

A torrid second wave held back India’s economic rebound in 2Q, and we see only modest improvement in 3Q, even though the worst of the pandemic appears to be behind us. Mass vaccination will take many months, with only 5% of the population fully inoculated so far. Reopening the economy will have to be rather gradual as fears of a third wave of the pandemic, driven by the delta plus variant, have spread lately.

A favourable base effect (the economy contracted by 24% during April-June 2020) will help produce a large positive growth number in 2Q, but our Nowcast model estimates those effects to fade somewhat in 3Q, with growth easing to 6.8%. The risk to the outlook is characterised by contrasting factors—on the plus side the export engine could hum owing to strong external demand; on the negative side, domestic consumption and investment could get postponed by mobility restrictions; high fuel prices can also be a potential drag.

Despite ample liquidity, exceptionally low interest rates, and public sector support, private sector credit growth remains well below trend. India entered the pandemic on a weak ground, with the economy slowing substantially through the course of the 2019. The resulting balance sheet stress continues to act as a drag to the economy, although attempts to revive manufacturing have caught the attention of global investors. Strong capital inflow and favourable external accounts have held India in good stead during this challenging year. Near-term economic prospects for India however have yet to brighten considerably.





Indonesia

With no sign of respite from the pandemic, as infections and deaths hit record levels in early-July, Indonesia’s public health management struggles have spilled over into the third quarter. Construction has been severely hampered, credit growth remains weak, and near-zero tourism continues to be a major drag to economic activity. Favourable base effects will allow for 4.7% growth in 3Q, as per our Nowcast, but the underlying economic dynamic is substantially below-trend in Indonesia.

We see the economy likely to register no more than 4% growth this year, that too thanks to some tailwind to the commodity sector. At the same time, we see the risk to growth tilted to the downside, with hopes of opening the tourism/travel sector in a meaningful manner this year fading swiftly.

The longer it takes to vaccinate the masses, the deeper the risk of long-term scarring to economic potential. Indonesia averaged a healthy 5.3% real GDP growth during the past decade, which could be very difficult to replicate in this decade unless an exceptionally strong multi-year post-pandemic recovery is on the cards. We take some comfort from the fact that the authorities have not allowed their reform initiatives to be held back by the economic downturn, which would be essential to make up for the below-trend output of last year and this year. Taking the IMF’s GDP forecast for Indonesia going out to 2026, we estimate that even at that point the level of real GDP would be around 7% below trend.






Singapore

As it endeavors to reach the critical threshold two-thirds of the population being vaccinated, allowing for significant easing of mobility restrictions, Singapore’s economy remains caught between still-sound fundamentals and a not yet clear outlook. If variant-related transmissions remain under check, the coming months will be marked by a steady stream of easing measures, which ought to help consumer and business sentiments, pushing up retail sales, travel/tourism, events-related spending, loans, and investment. Already, low rates have galvanised the property market, and strong demand in China and the US has helped boost exports.

Our Nowcasting model is tracking 5.8% growth in 3Q, taking into account normalisation of base effects on trade and production figures. Travel would be up sharply relative to a year ago, but that’s not saying much as it would still be drastically below the long-run trend.

We see possible upside risks to the outlook in 4Q, subject to the major caveat of no slippage with pandemic management. Barring that unfortunate scenario, the economy could boom in 4Q around the type of re-opening dynamic playing out the in the US presently. Growth in that eventuality could exceed our annual forecast of 6.3%.






To read the full report, click here to Download the PDF.

Taimur Baig, Ph.D. 泰穆爾 貝格, Ph.D.

Chief Economist - G3 & Asia 集團首席經濟學家 - G3 及亞洲
taimurbaig@dbs.com

Daisy Sharma

Data Analytics
daisy@dbs.com

Subscribe here to receive our economics & macro strategy materials.
To unsubscribe, please click here.
The information herein is published by DBS Bank Ltd. It is based on information obtained from sources believed to be reliable, but the Group does not make any representation or warranty, express or implied, as to its accuracy, completeness, timeliness or correctness for any particular purpose. Opinions expressed are subject to change without notice. Any recommendation contained herein does not have regard to the specific investment objectives, financial situation & the particular needs of any specific addressee. The information herein is published for the information of addressees only & is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate legal or financial advice. The Group, or any of its related companies or any individuals connected with the group accepts no liability for any direct, special, indirect, consequential, incidental damages or any other loss or damages of any kind arising from any use of the information herein (including any error, omission or misstatement herein, negligent or otherwise) or further communication thereof, even if the Group or any other person has been advised of the possibility thereof. The information herein is not to be construed as an offer or a solicitation of an offer to buy or sell any securities, futures, options or other financial instruments or to provide any investment advice or services. The Group & its associates, their directors, officers and/or employees may have positions or other interests in, & may effect transactions in securities mentioned herein & may also perform or seek to perform broking, investment banking & other banking or finan­cial services for these companies. The information herein is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation. Sources for all charts & tables are CEIC & Bloomberg unless otherwise specified.

DBS Bank Ltd., 12 Marina Blvd, Marina Bay Financial Center Tower 3, Singapore 018982. Tel: 65-6878-8888. Company Registration No. 196800306E. DBS Bank Ltd., Hong Kong SAR Branch, a company incorporated in Singapore with limited liability. 18th Floor, The Center, 99 Queen’s Road Central, Central, Hong Kong SAR.

The information set out in this website ("Information") is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in any locality, state, country, or other jurisdiction (including but not limited to citizens or residents of the United States of America) where such distribution, publication, availability or use would be contrary to law or regulation. This Information is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction (including but not limited to the United States of America) where such an offer or solicitation would be contrary to law or regulation. This Information is published for general circulation only and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person. Visitors accessing this website should always seek advice from an independent financial adviser regarding the suitability of the Information referred to herein (taking into account the specific investment objectives, financial situation and/or particular needs of each person in receipt of the Information) before making any investment and/or any purchase in reliance of the Information. Please refer to the actual research publications for important disclaimers and disclosures, where applicable.